Although molecular targeted therapy against mutated driver oncogene such as EGFR or ALK has improved the survival rates of patients with lung cancer, BMs remain an important cause of morbidity and are associated with progressive neurologic deficits (8, 9). Here, EGFR is linked to lung cancer.